Monkeypox Could Easily Mutate To Resist Antiviral Treatment, FDA Says

FDA recommends providers be cautious in deciding to which patients with monkeypox they prescribe tecovirimat, or TPOXX, out of concern that the virus could easily evolve to resist the antiviral treatment with a small change to one protein. At a press briefing on the administration’s monkeypox response Thursday (Sept. 15), National Institute of Allergies and Infectious Diseases Director Anthony Fauci said an upcoming study on the monkeypox treatment tecovirimat will examine potential resistance to the drug, among other factors. The...